Multicenter Evaluation of Nine Commercial Kits for the Quantitation of Anticardiolipin Antibodies

Summary

The performances of nine commercial kits and an in-house method (HM) for the quantitation of anticardiolipin antibodies (ACA) have been evaluated in a multicenter study. Ninety control and patient samples and six standards from Louisville University were run with kits and with the HM. Marked differences in positivity rate between kits were observed, ranging from 31 to 60% for IgG and 6 to 50% for IgM. Concordance between kits occurred in 59 and 51% of samples for IgG and IgM respectively. Concordance coefficients (kappa) ranged from 0.13 to 0.92. Slopes of regression lines between the declared units of Louisville standards and the units measured from the calibrators of the kits showed great diversity and ranged from 0.159 to 0.931 for IgG and from 0.236 to 0.836 for IgM. The β₂-glycoprotein I (β₂-GPI) content of the dilution buffers and the wells supplied with the kits revealed noticeable differences. However samples containing anti-(β₂-GPI antibodies were classified similarly by all but one kit. In contrast the ability to measure samples devoid of anti-β₂-GPI antibodies differed markedly between the kits.

This study shows that differences in positivity rates between the commercial kits may contribute to the differences in ACA prevalence rate found in the literature. The choice of cut-off levels may partly explain the moderate concordance between the kits. In addition some samples behave very differently depending on the kits. In spite of the expression of results in PL units, standardization of ACA assays has not been achieved.

• References

• 1 Loizou S, McCrea JD, Rudje AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-745
• 2 Peaceman AM, Silver RK, Macgregor SC, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166: 1780-1787
• 3 Cowchock S, Fort J, Munoz S, Norberg R, Maddrey W. False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion. Clin Exp Immunol 1988; 73: 289-294
• 4 Reber G, Tremblet C, Bernard C, Mermillod B, de Moerloose P. Anticardiolipin antibodies and thrombosis: buffers' influence on the detection and quantitation of anticardiolipin antibody measured by ELISA. Thromb Res 1990; 57: 215-226
• 5 Rupin A, Gruel Y, Leroy J, Bardos P. Anticardiolipin in systemic lupus erythematosus Association with thrombosis if measured by ELISA with adult bovine serum as buffer rather than fetal calf serum. Thromb Res 1990; 60: 415-420
• 6 Firer MA, Spivak T, Schoenfeld Y, Slor H. The effects of incubation temperature and coating procedure on the measurement of antibodies to cardiolipin. J Immunol Methods 1991; 143: 31-39
• 7 Rupin A, Gruel Y, Watier H, Girard AC, Leroy J, Bardos P. ELISA for the detection of anticardiolipin antibodies High specificity based on the use of adult bovine serum as buffer and substraction of non-specific binding. J Immunol Methods 1991; 138: 225-231
• 8 Rupin A, Reber G, Bardos P, de Moerloose P. Preferential use of dilution of single sera than mixture of sera to standardize the quantitation of anti-cardiolipin antibodies. Thromb Res 1994; 75: 465-471
• 9 Cheng HM. Antigenicity of cardiolipin in Tween 20. J Immunol Methods 1988; 14: 279-280
• 10 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 11 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ C, Barbui T, Zwaal RF A, Bevers EM. Anticardiolipin anti-bodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
• 12 Chamley LW, Pattison NS. Anomalous anticardiolipin antibody results may be due to cofactor variability. Am J Hematol 1991; 37: 289 (letter)
• 13 Harris EN, Gharavi AE, Hughes GR V. Anticardiolipin antibody testing: The need for standardization. Arthritis Rheum 1987; 30: 835-836
• 14 Harris EN, Gharavi AE, Patel SP, Hughes GR V. Evaluation of the anticardiolipin antibody test: Report of a standardization workshop held April 4th, 1986. Clin Exp Immunol 1987; 68: 215-222
• 15 Harris EN. The second international anti-cardiolipin standardization work- shop/The Kingston anti-phospholipid antibody (KAPS) study group. Am J Clin Pathol 1990; 94: 476-484
• 16 Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth International Symposium on Antiphospholipid Antibodies Am J Clin Pathol 1994; 101: 616-624
• 17 Abuaf N, Meyer O, Laperche S, Pieron D, Laroche P, Rajoely B, Rouquette AM. Conclusions du 1er atelier français de standardisation du dosage des anticorps anticardiolipine associés à la pathologie autoimmune. Ann Biol Clin 1994; 52: 365-373
• 18 Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β₂-glycoprotein I as antigen. J Immunol Methods 1991; 143: 223-229
• 19 Cohen J. A coefficient of agreement for nominal scales. Educ Psych Meas 1960; 20: 37-46
• 20 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-3891
• 21 Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moustopoulos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol 1987; 44: 297-307
• 22 Meyer O, Cyna L, Bourgeois P, Kahn MF, Ryckewaert A. Profile and cross-reactivities of antiphospholipid antibodies in systemic lupus erythematosus and syphillis. Clin Rheumatol 1987; 6: 369-377
• 23 Keane A, Woods R, Dowding V, Roden D, Barry C. Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol 1987; 26: 557-565
• 24 Coulam CB, McIntyre JA, Wagenknecht D, Rote N. Interlaboratory inconsistencies in detection of anticardiolipin antibodies. Lancet 1990; 335: 865 (Letter)
• 25 Peter J. Cardiolipin antibody assay. Lancet 1990; 1: 1405 (Letter)
• 26 Loizou S. Anticardiolipin kits: Techniques of antiphospholipid antibody measurements. Clin Immunol 1991; 11: 41-47
• 27 de Moerloose P, Reber G, Vogel JJ. Anticardiolipin antibody determination: comparison of three ELISA assays. Clin Exp Rheumatol 1990; 8: 575-577
• 28 Reyes H, Dearing L, Schoenfeld Y, Peter JB. Antiphospholipid antibodies: a critique of their heterogeneity and hegemony. Seminars Thromb Hemostas 1994; 20: 89-100
• 29 Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid- β₂-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81
• 30 Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass restriction of anti-ß2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-315